imphatec is a London-based synthetic biology pharmaceutical company developing a customisable-dose subcutaneous implant platform for chronic and long-term conditions. Its implants release personalised medication doses over an extended period with no patient input required, aiming to replace daily tablets — starting with hypothyroidism — and deliver what the company calls a pill-free future. Co-founded by James Catt and Dr Hassan Morad (CSO), the company has successfully progressed its implants through pre-clinical stages and is working toward human clinical trials.
1
Round
1
Industry
5
Tags
Oct 27, 2026
Latest raise
Funding activity · 1 round
Oct 27, 2026
GBP 1.5M
Seed
Led by Synbioven
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
